Comparing two medications for pain relief after root canal treatment
Comparing Trypsin-Chymotrypsin and Naproxen Sodium for Post-endodontic Treatment Pain: a Randomized Controlled Trial
This study is testing whether a new pain relief medication works better than a common one for people who have pain after a root canal treatment.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 45 Years |
| Sex | All |
| Sponsor | Dow University of Health Sciences Academic / other |
| Locations | 1 site (Karachi, Sindh) |
| Trial ID | NCT06562816 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate the effectiveness of Trypsin-Chymotrypsin versus Naproxen Sodium in reducing pain following root canal treatment in patients with symptomatic irreversible pulpitis. Conducted as a triple-blinded, parallel, randomized controlled trial, 100 patients will be randomly assigned to receive either medication after their treatment. Pain levels will be measured at multiple intervals post-treatment using a numerical rating scale to determine which medication provides better pain relief. The study seeks to address the common issue of post-endodontic treatment pain that often discourages patients from seeking dental care.
Who should consider this trial
Good fit: Ideal candidates are healthy adults aged 18-45 with symptomatic irreversible pulpitis scheduled for endodontic treatment.
Not a fit: Patients requiring emergency dental treatment or those with systemic diseases or allergies to the study medications may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved pain management options for patients undergoing root canal treatments.
How similar studies have performed: Previous studies have explored alternative pain management strategies, but the specific comparison of Trypsin-Chymotrypsin and Naproxen Sodium in this context is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Both male and female, healthy patients (ASA class 1). * Patients between the age group of 18-45 years. * Patients who are appointed for endodontic treatment. * Maxillary or mandibular teeth diagnosed with symptomatic irreversible pulpitis based on delayed responses to vitality tests. Exclusion Criteria: * Patients who will require emergency dental treatment. * Teeth with any form of peri-apical lesion will be excluded. * Patient who have taken analgesics within 24 hours prior to the treatment. * Patients with known hypersensitivity or allergy to any of the study medications. * Patients with any systemic disease such as uncontrolled diabetes, gastric ulcers, bleeding disorders, or cardiovascular problems. * Pregnant or lactating women and pediatric patients.
Where this trial is running
Karachi, Sindh
- Dow University of Health Sciences — Karachi, Sindh, Pakistan (Recruiting)
Study contacts
- Principal investigator: Dr. Hafsa Zaki — Duhs
- Study coordinator: Dr. Hafsa Zaki, BDS
- Email: hafsazaki99@hotmail.com
- Phone: +923462746052
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.